Phase II multicenter open-label study of carboplatin and pegylated liposomal doxorubicin in uterine and cervical malignancies

International Journal of Gynecological Cancer

Volumn 15, Issue 5, 2005, Pages 799-806

  Le L H ^a   Swenerton, K D ^b   Elit, L ^c   Provencher, D M ^d   Stuart, G C E ^e   Le, T ^f   Lee, U ^g   Rodgers, A ^h   Pond, G R ^a   Hu, H ^a   Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Vancouver Cancer Centre   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d NOTRE DAME HOSPITAL   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g Fraser Valley Cancer Centre   (Canada)

^h INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Carboplatin; Cervical cancer; Malignant mixed M llerian tumors; Pegylated liposomal doxorubicin; Uterine cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BREATHING DISORDER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERUS CANCER; VOMITING;

ADOLESCENT; ADULT; BLOOD CELL COUNT; CARBOPLATIN; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; POLYETHYLENE GLYCOLS; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 28944431864     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00139.x     Document Type: Article

References (51)

1. American Cancer Society I. Cancer facts & figures 2002. Atlanta, GA: American Cancer Society, 2002.
2. Lentz SS. Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol 1994;21:100-6.
3. Fleming GF, Brunetto VL, Mundt AJ, Burks RT, Look KY, Reid G. Randomized trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 2002;21:807.
4. Long HJ 3rd, Cross WG, Wieand HS et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 1995;57:235-9.
5. Lorvidhaya V. Epirubicin and cisplatin in recurrent, metastatic or advanced carcinoma of the cervix. Gan To Kagaku Ryoho 1995;22(Suppl. 3):252-5.
6. Papadimitriou CA, Dimopoulos MA, Giannakoulis N et al. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. Cancer 1997;79:2391-5.
7. Lissoni A, Gabriele A, Gorga G et al. Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 1997;8:969-72.
8. Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991;9:1962-6.
9. Judson I, Radford JA, Harris M et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-7.
10. Garcia AA, Kempf RA, Rogers M, Muggia FM. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol 1998;9:1131-3.
11. Chidiac T, Budd GT, Pelley R et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs 2000;18:253-9.
12. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54(Suppl. 4):15-21.
13. Hong RL, Tseng YL. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 2001;91:1826-33.
14. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001;19:424-36.
15. Northfelt DW, Martin FJ, Working P et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
16. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559-93.
17. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
18. Bennett CL, Golub RM, Stinson TJ et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:460-5.
19. Northfelt DW, Dezube BJ, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51.
20. Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683-91.
21. Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-17.
22. Schwonzen M, Kurbacher CM, Mallmann P. Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer. Anticancer Drugs 2000;11:681-5.
23. Sparano JA, Malik U, Rajdev L, Sarta C, Hopkins U, Wolff AC. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001;19:3117-25.
24. Gebbia V, Mauceri G, Fallica G et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 2002;63:23-30.
25. Gogas H, Papadimitriou C, Kalofonos HP et al. Neo-adjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002;13:1737-12.
26. Hong RL, Tseng YL, Chang FH. Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. Ann Oncol 2000;11:349-53.
27. Israel VP, Garcia AA, Roman L et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Gynecol Oncol 2000;78:143-7.
28. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
29. Muggia F, Hamilton A. Phase III data on Caelyx in ovarian cancer. Eur J Cancer 2001;37(Suppl. 9):S15-8.
30. Gibbs DD, Pyle L, Allen M et al. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer 2002;86:1379-84.
31. Kavanagh J, Verschraegen C, Levenback C et al. A phase II study to evaluate the efficacy and toxicity of carboplatin plus Doxil administered intravenously as a single infusion every 28 days to women with advanced or recurrent squamous cell carcinoma of the cervix. Proc Am Soc Clin Oncol 2000;19:1561.
32. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
33. Jelliffe R. Letter: Creatinine clearance: bedside estimate. Ann Int Med 1973;79:604-5.
34. Gehan E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346-53.
35. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000;78:212-6.
36. McMeekin DS, Gordon A, Fowler J et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003;90:64-9.
37. Hald I, Salimtschik M, Mouridsen HT. Tamoxifen treatment of advanced endometrial carcinoma. A phase II study. Eur J Gynaecol Oncol 1983;4:83-7.
38. van Wijk FH, Lhomme C, Bolis G et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003;39:78-85.
39. Pawinski A, Tumolo S, Hoesel G et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol 1999;86:179-83.
40. Poplin EA, Liu PY, Delmore JE et al. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study. Gynecol Oncol 1999;74:432-5.
41. Wadler S, Levy DE, Lincoln ST, Soori GS, Schink JC, Goldberg G. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 2003;21:2110-4.
42. Dimopoulos MA, Papadimitriou CA, Georgoulias V et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 2000;78:52-7.
43. Gebbia V, Testa A, Borsellino N, Ferrera P, Tirrito M, Palmeri S. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen. Ann Oncol 2001;12:767-72.
44. Aapro MS, Van Wijk FH, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003;14:441-8.
45. Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2003;24:323-6.
46. Chitapanarux I, Tonusin A, Sukthomya V, Charuchinda C, Pukanhapan N, Lorvidhaya V. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol 2003;89:402-7.
47. Papadimitriou CA, Sarris K, Moulopoulos LA et al. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. J Clin Oncol 1999;17:761-6.
48. Gebbia V, Caruso M, Testa A et al. Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix. Oncology 2002;63:31-7.
49. Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989;161:309-12.
50. Ramondetta LM, Burke TW, Jhingran A et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 2003;90:529-36.
51. Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus. Gynecol Oncol 1995;56:370-5.